QED Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:N/A
Industry:Biotech
Founded:2018
Lead Investor(s):BridgeBio Pharma

Industry Ranking

Estimated Revenue & Financials

  • QED Therapeutics's estimated annual revenue is currently $9.9M per year.
  • QED Therapeutics received $65.0M in venture funding in January 2018.
  • QED Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • QED Therapeutics has 64 Employees.
  • QED Therapeutics grew their employee count by 100% last year.
  • QED Therapeutics currently has 4 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
DiaCarta
$7M4510%N/A-N/A
Geron Corporati...
N/A205N/AN/A-N/A
Rigel Pharmaceu...
$46.8M3024%N/A-N/A
Althea Technolo...
$22.3M144N/AN/A-N/A
INOVA Diagnosti...
$44.3M286N/AN/A-N/A
10X Genomics
$101.2M65346%N/A-N/A
ProTrials Resea...
$33.3M2153%N/A-N/A
Advanced Cell D...
$28.7M1858%N/A-N/A
The J. Craig Ve...
$39.4M254N/AN/A-N/A
CellMax Life
$6.5M4214%N/A-N/A
Missing a competitor? Contribute!?
Submit

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.

keywords:N/A

64

Number of Employees

$9.9M

Revenue (est)

4

Current Jobs

100%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

QED Therapeutics News

04/01/2019 - Preclinical Data Demonstrates the Potential of QED ...

SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- QED Therapeutics announced today the presentation of preclinical data demonstrating the ...

06/03/2019 - QED Therapeutics Presents New Data on the Potential for ...

SAN FRANCISCO, June 3, 2019 /PRNewswire/ -- QED Therapeutics announced today the presentation of data demonstrating the clinical ...

09/05/2019 - BridgeBio Launches New Subsidiary to Tackle Limb-Girdle ...

Sarepta Therapeutics is also focused on the disease. ... comes about a year after BridgeBio launched QED Therapeutics to develop infigratinib, ...

QED Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-01-31$65.0MUndisclosedBridgeBio PharmaArticle